What is the recommended treatment and management for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)?

Treatment of CADASIL

There is no disease-modifying therapy currently available for CADASIL; treatment focuses on hypertension control as the only intervention proven to slow cerebral small-vessel disease progression, combined with symptomatic management and vascular risk factor modification. 1

Primary Management Strategy

Blood Pressure Control

• Aggressive hypertension management is the cornerstone of CADASIL treatment, as it is the only intervention demonstrated to reduce the risk of cerebral small-vessel disease progression 1
• Target systolic blood pressure <140 mmHg, though optimal targets specific to CADASIL remain undefined 2
• Antihypertensive medication should be administered and titrated to achieve these targets 3

Antiplatelet Therapy

• Aspirin 75-325 mg daily is recommended for patients with CADASIL who have experienced ischemic stroke or TIA 4, 3
• For patients with stroke/TIA, alternative single antiplatelet options include clopidogrel 75 mg daily or aspirin plus extended-release dipyridamole (25/200 mg twice daily) 4, 5
• Antiplatelet agents are preferred over oral anticoagulation unless there is a separate indication (e.g., atrial fibrillation) 4, 3
• The combination of aspirin plus clopidogrel is not recommended beyond 3 months after stroke or TIA due to increased bleeding risk without proven benefit 6, 3

Lipid Management

• High-dose statin therapy is recommended to reduce LDL cholesterol below 100 mg/dL, with consideration of targeting near or below 70 mg/dL in patients who have sustained ischemic stroke 3, 5
• Statins should be administered regardless of baseline cholesterol levels given their pleiotropic vascular protective effects 3

Symptomatic Management

Migraine Treatment

• Standard migraine prophylaxis and acute treatment can be offered, though specific efficacy data in CADASIL are limited 2, 7
• Avoid vasoconstrictive agents (triptans, ergotamines) when possible due to theoretical concerns about exacerbating small-vessel disease, though no definitive contraindication exists 8

Mood Disorders

• Depression and mood disturbances should be treated with standard antidepressant therapy 2, 7
• Cognitive behavioral therapy and psychiatric consultation may be beneficial 8

Cognitive Impairment and Dementia

• Cholinesterase inhibitors and memantine may be considered for symptomatic treatment of vascular dementia, though evidence specific to CADASIL is lacking 8, 9
• Cognitive rehabilitation and supportive care are important components 2

Risk Factor Modification

Smoking Cessation

• All patients who smoke must be advised to quit and offered smoking cessation interventions 3
• Smoking accelerates atherosclerosis and vascular disease progression 3

Diabetes Management

• Glucose control through diet, exercise, and glucose-lowering medications is recommended, though intensive glucose lowering to HbA1c <7.0% has not been proven to prevent stroke in this population 6, 3

Physical Activity

• Regular moderate physical activity is recommended as part of comprehensive vascular risk reduction 5

Important Contraindications and Cautions

Avoid Anticoagulation

• Full-intensity anticoagulation with unfractionated heparin or low-molecular-weight heparin is not recommended for acute ischemic stroke or TIA in CADASIL unless there is a separate compelling indication 6, 3
• The risk of intracerebral hemorrhage may be elevated in CADASIL patients 2

Revascularization Procedures

• Carotid endarterectomy and stenting are not indicated for CADASIL, as the disease involves small vessels rather than large-vessel atherosclerotic stenosis 3, 10
• If coronary artery disease coexists, percutaneous or surgical revascularization carries significant peri-procedural stroke risk and requires careful multidisciplinary evaluation 11

Monitoring and Follow-Up

• Regular neurological assessment to monitor disease progression 2
• Annual evaluation of cardiovascular risk factors and treatment adherence 10
• Blood pressure monitoring at every clinical contact 10
• Neuroimaging surveillance is not standardized but may be considered to assess disease burden 2, 7

Emerging and Investigational Therapies

• No disease-modifying therapies are currently approved, in contrast to other hereditary small-vessel disorders (ADA2, COL4A1, TREX1) 1
• Experimental approaches targeting NOTCH3 aggregation, vascular smooth muscle cell dysfunction, and neurotrophic support are under investigation but remain unproven 12, 8
• Cerebrolysin showed some benefit in murine models but requires human validation 13

Key Clinical Pitfalls

• Do not delay genetic testing when CADASIL is suspected based on characteristic imaging findings (anterior temporal lobe white matter hyperintensities, external capsule involvement) and family history 2, 7
• Do not assume all strokes in CADASIL patients are due to small-vessel disease—evaluate for concurrent large-vessel atherosclerosis or cardioembolic sources 2
• Do not use dual antiplatelet therapy long-term beyond the acute period, as bleeding risk outweighs benefit 6, 3